Clinical Development
LBH589 (Panobinostat)
Protocol CLBH589B2402B / [STUDY_ID_REMOVED]
An 
open -label multi- center single agent panobinostat roll -
over protocol for patients w ho hav e completed a prev ious 
Novartis -sponsored panobinostat study and are judged by 
the inv estigator to benefit from continued single agent 
panobinostat treatment
Authors
Document type Amended Protocol Version
EUDRACT number 2012 -005252 -41
Version number 01(Clean )
Development phase II
Document status Final
Release date 11-Mar-2016
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Template version 19-Nov-2015

Novartis Confidential Page 2
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 5
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 8
Amendment 01 .................................................................................................................... 9
Protocol summary :............................................................................................................. 12
1Background ........................................................................................................................ 14
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 14
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 15
1.2.1 Overview of panobinostat ..................................................................... 15
2Rationale ............................................................................................................................ 17
2.1 Study  rationale and purpose ................................................................................... 17
2.2 Rationale for the stud y design ............................................................................... 18
2.3 Rationale for dose and regimen selection .............................................................. 18
2.4 Rationale for choice of combination drugs............................................................ 18
2.5 Rationale for choice of comparators drugs ............................................................ 18
2.6 Risks and benefits .................................................................................................. 18
3Objectives and endpoints ................................................................................................... 19
4Study  design ...................................................................................................................... 21
4.1 Description of stud y design ................................................................................... 21
4.2 Timing of interim anal yses and design adaptations ............................................... 22
4.3 Definition of end of study ...................................................................................... 22
4.4 Early study termination .......................................................................................... 22
5Population .......................................................................................................................... 22
5.1 Patient population .................................................................................................. 22
5.2 Inclusion criteria .................................................................................................... 22
5.3 Exclusion criteria ................................................................................................... 23
6Treatment ........................................................................................................................... 24
6.1 Study  treatment ...................................................................................................... 24
6.1.1 Dosing regimen ..................................................................................... 24
6.1.2 Ancillary  treatments .............................................................................. 25
6.1.3 Rescue medication ................................................................................ 25
6.1.4 Guidelines for continuation of treatment .............................................. 25
6.1.5 Treatment duration ................................................................................ 25

Novartis Confidential Page 3
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
6.1.6 Starting dose rationale ........................................................................... 25
6.2 Dose modifications ................................................................................................ 26
6.2.1 Non-Cardiac Toxicity  Dose Modifications ........................................... 26
6.2.2 Thrombocy topenia ................................................................................ 26
6.2.3 Gastrointestinal toxicity ........................................................................ 27
6.2.4 Neutropenia ........................................................................................... 27
6.2.5 Follow-up for to xiciti es......................................................................... 28
6.2.6 Dose modification of panobinostat for prolonged QTcF interval ......... 28
6.2.7 Suggested management of selected adverse events .............................. 29
6.2.8 Follow up on potential drug -induced liver injury  (DILI) cases ............ 30
6.3 Concomitant medications ...................................................................................... 31
6.3.1 Use of Bisphosphonates (or other concomitant agents) ........................ 33
6.4 Patient numbering, treatment as signment or randomization ................................. 33
6.4.1 Patient numbering ................................................................................. 33
6.4.2 Treatme nt assignment or randomization ............................................... 33
6.4.3 Treatment blinding ................................................................................ 33
6.5 Study  drug preparation and dispensation ............................................................... 33
6.5.1 Study  treatment packaging and labeling ............................................... 33
6.5.2 Drug supply  and storage ........................................................................ 33
6.5.3 Study  drug compliance and accountabilit y ........................................... 34
6.5.4 Disposal and destruction ....................................................................... 34
7 Visit schedule and assessments ......................................................................................... 34
7.1 Study  flow and visit schedule ................................................................................ 34
7.1.1 Molecular pre -screening ........................................................................ 36
7.1.2 Screening ............................................................................................... 36
7.1.3 Treatment period ................................................................................... 36
7.1.4 Pregnancy  and assessment of fertility ................................................... 36
7.1.5 Discontinuation of study treatment ....................................................... 37
7.1.6 Withdrawal of consent .......................................................................... 38
7.1.7 Follow up for safet y evaluations ........................................................... 39
7.1.8 Lost to f ollow-up................................................................................... 39
7.2 Assessment ty pes................................................................................................... 39
7.2.1 Efficacy  assessments ............................................................................. 39
7.2.2 Other assessments ................................................................................. 39
7.2.3 Safety  and tolerability  assessments ....................................................... 39
7.2.4 Pharmacokinetics .................................................................................. 39

Novartis Confidential Page 4
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
7.2.5 Resource utilization ............................................................................... 40
7.2.6 Patient reported outcomes ..................................................................... 40
8Safety  monitoring and reporting ........................................................................................ 40
8.1 Adverse events ....................................................................................................... 40
8.1.1 Definitions and reporting ...................................................................... 40
8.1.2 Laboratory  test abnormalities ................................................................ 41
8.1.3 Adverse events of special interest ......................................................... 42
8.2 Serious adverse events ........................................................................................... 42
8.2.1 Definitions............................................................................................. 42
8.2.2 Reporting............................................................................................... 42
8.3 Emergency  unblinding of treatment assignment ................................................... 43
8.4 Pregnancies ............................................................................................................ 44
8.5 Warnings and precautions ...................................................................................... 44
8.6 Data Monitoring Committee .................................................................................. 44
8.7 Steering Committee ............................................................................................... 44
9Data collection and management ....................................................................................... 44
9.1 Data confidentiality ............................................................................................... 44
9.2 Site monitoring ...................................................................................................... 45
9.3 Data collection....................................................................................................... 45
9.4 Database management and quality  control ............................................................ 46
10Statistical methods and data anal ysis................................................................................ 46
10.1 Analy sis sets .......................................................................................................... 46
10.1.1 Full Anal ysis Set ................................................................................... 46
10.1.2 Safety  Set .............................................................................................. 46
10.1.3 Dose -determining anal ysis set............................................................... 46
10.2 Patient demographics/other baseline characteristics ............................................. 46
10.3 Treatments (stud y treatment, compliance) ............................................................ 46
10.4 Primary  obje ctive ................................................................................................... 46
10.4.1 Variable ................................................................................................. 47
10.4.2 Statistical hy pothesis, model, and method of analy sis.......................... 47
10.4.3 Handling of missing values/censoring/discontinuations ....................... 47
10.4.4 Supportive analy ses............................................................................... 47
10.5 Secondary  objectives ............................................................................................. 47
10.5.1 Key secondary  objective(s) ................................................................... 47
10.5.2 Other secondary  efficacy objectives ..................................................... 47
10.5.3 Safety  objectives ................................................................................... 47

Novartis Confidential Page 5
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
10.6 Interim anal ysis...................................................................................................... 48
10.7 Sample size calculation.......................................................................................... 48
10.8 Power for anal ysis of key secondary  variables...................................................... 48
11 Ethical considerations and administrativ e procedures ...................................................... 48
11.1 Regulatory and ethical compliance ........................................................................ 48
11.2 Respon sibilities of the investigator and IRB/ IEC/REB ......................................... 48
11.3 Informed consent procedures................................................................................. 48
11.4 Discontinuation of the study .................................................................................. 49
11.5 Publication of study  protocol and results ............................................................... 49
11.6 Study  documentation, record keeping and re tention of documents ....................... 49
11.7 Confidentiality  of study  documents and patient records ....................................... 50
11.8 Audits and inspections........................................................................................... 50
11.9 Financial disclosures .............................................................................................. 50
12Protocol adherence ............................................................................................................ 51
12.1 Amendments to the protocol .................................................................................. 51
13References (available upon request) .................................................................................. 52
14Appendices ........................................................................................................................ 53
14.1 Concomitant medication........................................................................................ 53
14.1.1 Medi cations which are k nown toprolong theQTinterval a nd/or
induceTorsades de point es ventricular arrhyt hmia should be
avoided .................................................................................................. 53
14.1.2 Medications which are known strong CYP3A4/5 inhibitors to be 
avoided .................................................................................................. 54
14.1.3 Medi cations which are k nown CYP 2D6 subst rates tobe used with
caution ................................................................................................... 55
List of figures
Figure 4 -1 Study  design .......................................................................................... 22

Novartis Confidential Page 6
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
List of tables
Table 3 -1 Objectives and related endpoints .......................................................... 20
Table 6 -1 Dose and treatment schedule................................................................. 24
Table 6 -2 Thrombocy topenia dose modifications ................................................. 27
Table 6 -3 Diarrhea dose modifications ................................................................. 27
Table 6 -4 Neutropenia dose modifications ............................................................ 27
Table 7 -1 Visit evaluation schedule ...................................................................... 35
Table 14 -1 Medications which are known to prolong the QT interval and/or 
induce Torsades de Pointes to be avoided ............................................. 53
Table 14 -2 Medic ations whichareknown s trong CYP 3A4/ 5 inhibitorsto be
used with caution................................................................................... 55
Table 14 -3 M edications whi chareknown CYP 2D6 substratesto be used with 
caution................................................................................................... 56

Novartis Confidential Page 7
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
List of abbreviations
AE Adverse Event
CRF Case Report/Record Form
CRF Case report/record form
CRO Contract Research Organization
CRO Contract Research Organization
CSR Clinical study report
CTCL Cutaneous T -cell lymphoma 
DACis Deacetylase inhibitors
DDI Drug -drug interaction
DS&E Drug Safety and Epidemiology
EC Ethics Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
EOT End Of Treatment 
HDACs Histone deacetylases
i.v. Intravenous(ly)
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IIT Investigator -Initiated Trial
IRB Institutional Review Board
LBH589 Panobinostat
o.d. Omnia die /once a day
OGD&GMA Oncology Global Development & Global Medical Affairs
p.o. Per os /by mouth/orally
QOW Every other week
QW Every week
s.a. Single agent 
SAE Serious Adverse Event
SOP Standard Operating Procedure
SUSAR Suspected Unexpected Serious Adverse Reactions
TIW Three -times -a-week

Novartis Confidential Page 8
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
Inves tigational drug The study drug or treatment whose properties are being tested in the study; 
this definition is consistent with US CFR 21 Section 312.3 and is synonymous 
with “investigational new drug.”
Investigational treatment Drug whose properties are b eing tested in the study as well as their 
associated placebo and active treatment controls (when applicable). This also 
includes approved drugs used outside of their indication/approved dosage, or 
that are tested in a fixed combination. Investigational treatment generally does 
not include other study treatments administered as concomitant background 
therapy required or allowed by the protocol when used in within approved 
indication/dosage
Other study treatment Any drug administered to the patient as part of the required study procedures 
that was not included in the investigational treatment
Parent Study The original Novartis -sponsored, Oncology Global Development & Global 
Medical Affairs ( OGD&GMA ) study, where the patient was first enrolled and 
received t reatment
Patient Number A unique identifying number assigned to each patient/subject who enrolls in 
the study
Roll-over study A roll -over study allows patients from multiple parent studies spanning multiple 
indications to continue to be treated within o ne study after the completion of 
the parent study/ies
Study treatment Includes any drug or combination of drugs in any study arm administered to 
the patient (subject) as part of the required study procedures, including 
placebo and active drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non -investigational 
treatments in combination.

Novartis Confidential Page 9
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Amendment 01 
Amendment rationale
The main purpose of the amendment is to change the primary  endpoint to safet y to better 
characterize the long-term safet y of the compound.  In addition, the protocol has been 
amended to include the collection of all AEs (including non-serious AEs) and an investigator 
attestation of continued clinical benefit. 
This roll-over study  has been opened since 24-Jun-2013 with 9 total patients enrolled and 3 
patients ongoing. 
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following changes have been implemented: 
Section 1.2.1.2: Update dclinical experience section to include the results from a multicentre 
phase III study  in patients with relapsed or relapsed and refractory  multiple myeloma and 
included title for section 1.2.1.2.1 (Clinical pharmacokinetics and pharmacody namics).
Section 2.1: The purpose of the study  has been updated to better characterize the long -term 
safet y of s.a. oral panobinostat in patients who are on s.a. oral panobinostat treatment in a 
Novartis -sponsored study and are benefitting from the treatment as judged by  the investigator. 
Section 2.2: The rationale for the study  design has been updated to better characterize the 
long-term safety  of s.a. oral panobinostat in patients being treated in a current Novartis -
sponsored study and who are benefitting from treatment with s.a. oral panobinostat. 
Section 2.4 and 2.5 added per new protocol template. 
Section 2.6: Risks and Benefits section added per the new protocol template. 
Table 3-1: Updated with revised study  objectives.  The primary  objective is to evaluate long 
term safety  data. The secondary  objective is to evaluate clinical benefit as assessed by the 
investigator.
Section 4.1: Updated to clarify  that all adverse events and serious adverse events will be 
collected continuousl y throughout the study  and to specify that at every quarterl y visit, the 
investigator is required to confirm that the patient continues to have clinical benefit and may 
continue receiving study  treatment . Updated to include study  termination by sponsor as 
another possible criterion for discon tinuation.
Section 5.3 Exclusion criterion #4 updated to clarify  highly  effective contraception methods
and duration of contraception use after stopping study  treatment (i.e. 6 months for male 
participants and 3 months for females) . Exclusion criterion #5added to exclude sexually  
active males unless they use a condom during intercourse while taking study  drug and for 6 
months after stopping treatment and should not father a child in this period. A condom is 
required to be used also by vasectomized men as well as during intercourse with a male 
partner in order to prevent delivery  of the drug via semen

Novartis Confidential Page 10
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Previous Section 6.1.5 (Dose escalation guidelines) re-located to section 6.2 per the new 
template.
Previous Section 6.1.6 (Treatment duration) updated to Section 6.1.5 was modified to specify 
that a t every  quarterl y visit, the investigator is required to confirm that the patient continues to 
have clinical benefit and may  continue receiving study  treatment .
Section 6.2 and 6.2.1 added per the new protocol templ ate. 
Section 6.3 added to include information for identify ing potential drug -induced liver injury . 
Previous Section 6.2 (Concomitant medications) updated to Section 6.4 and Section 6.4.1 
added per the new protocol template. 
Section 6.4 updated to clarif y that no other investigationl therap y should be given to patients 
and no anticancer agents other than the study  medication (panobinostat) should be given to 
patients during the study . If such agents are required for a patient then the patient must first b e 
withdrawn from the study. 
Sections 6.6 , 6.6.1 and 6.6.2 added /updated per the new protocol template. 
Table 7-1: Updated to include investigator attestation of clinical benefit at every  quarterl y 
visit, collection of all adverse events , relevant medical history , monthly  at home pregnancy 
testing for female patients of child bearing potential and the study  evaluation completion 
eCRF page at the end of the 30 day  safet y follow up.
Section 7.1.3: Updated to specify  that the investigator is required to confi rm that the patient 
continues to have clinical benefit at every  quarterly  visit and may continue receiving study 
treatment.
Section 7.1.4: Updated to include information on pregnancy  and assessment of fertility. 
Female patients of child bearing potential will now be required to perform monthly  home 
urine pregnancy  tests and complete a simple diary  with the dates and the outcome of the home 
urinary  test while on study  treatment and during safet y follow -up (30 days after the final dose 
of study  medication). A pregnancy  test (either with serum testing if routinely /locally  available 
or urine pregnancy  test) on female patients of child bearing potential is required at the final 
study  visit.
Section 7.1.5, 7.1.6, 7.1.8 and 7.2.3 added per the new protocol templat e. 
Section 7.1.5: Updated to include the completion of the study  evaluation completion eCRF 
page at the end of the 30 day safet y follow up.
Section 7.1.5.1: Updated to include study  termination by sponsor as another possible criterion
for discontinuation.
Section 7.1.7: Updated to include adverse events in safet y follow up period. 
Section 7.2.1: Updated to include investigator attestation of clinical benefit at every  quarterl y 
visit. 
Section 8: Updated with new AE/SAE reporting process. 
Section 9.1 updated per the new protocol template. 

Novartis Confidential Page 11
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Section 10: Updated statistical anal ysis section based on revised stud y objectives.
The protocol summary has also been updated to incorporate all the necessary  changes 
described above.
All instances of Oncology  Clinical Development & Medical Affairs (CD&MA) have been 
updated to Oncology  Global Development & Global Medical Affairs (OGD&GMA).
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) an d Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 12
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Protocol summary : 
Protocol number CLBH589B2402B
Title An open -label multi- center single agent panobinostat roll -over protocol for patients 
who have completed a previous Novartis- sponsored panobinostat study and are 
judged by the investigator to benefit from continued single agent panobinostat 
treatment
Brief title Study to allow access to single agent panobinostat for patients who a re on single 
agent panobinostat treatment in a Novartis- sponsored study and are benefiting 
from the treatment as judged by the investigator.
Sponsor and Clinical Phase Novartis, II.
Investigation type Drug.
Study type Interventional.
Purpose and ration ale The purpose of this study is to better characterize the long -term safety of single 
agent panobinostat in patients who are on single agent panobinostat treatment in a 
Novartis -sponsored, Oncology Global Development & Global Medical Affairs 
(OGD&GMA ) study and are benefiting from the treatment as judged by the 
investigator.
Primary Objective(s) and 
Key Secondary ObjectiveTo eva luate long term safety data ( SAEs and AEs )
Secondary Objectives To evaluate clinical benefit as assessed by the investigator
Study design This is a multi -center, open label study to better characterize the long -term safety
of patients being treated in current Novartis -sponsored Oncology OGD&GMA
studies and who are benefiting from treatment with single agent panobinostat. 
There w ill be no screening period for this study. Eligible patients are to be 
consented and can start their treatment with panobinostat as soon as they enter 
the study. All patients must report to the study site for their first visit at which time, 
a quarterly su pply of panobinostat can be dispensed to the patient.
Patients must return to the study center on quarterly (every 12 +/ - 2 weeks) basis 
for resupply of study medication at which time  drug dispensing and adverse event 
information will be collected. 
Patie nts will continue to be treated until they are no longer benefiting from 
panobinostat treatment, develop unacceptable toxicities, withdraw consent, are 
non-compliant to the protocol (i.e. pregnancy occurs, etc.), the investigator feels it 
is no longer in the patient’s best interest to continue panobinostat therapy or the 
patient dies, whichever comes first. 
A patient will reach the end of st udy when panobinostat treatment is permanently 
discontinued and the end of treatment visit has been performed. All patients must 
be followed up for safety evaluations for 30 days after the last dose of study 
treatment. Following this there are no further f ollow -up study visits.
The study is expected to remain open for 5 years or until such time that enrolled 
patients no longer need treatment with panobinostat, whichever comes earlier. 
Population Male and female patients, who are currently enrolled in a No vartis -sponsored, 
Oncology OGD&GMA panobinostat study, are benefiting from treatment with single 
agent panobinostat and have fulfilled all their requirements in the parent study. All 
objectives of the parent study must have been reached, and the study must be in 
the process of being completed & reported. 
Inclusion criteria Patient is currently enrolled in a Novartis -sponsored, Oncology Global 
Development & Global Medical Affairs study receiving single agent panobinostat 
and has fulfilled all their require ments in the parent study.
Patient is currently benefiting from the treatment with single agent panobinostat, as 
determined by the investigator. 
Patient has demonstrated willingness and compliance, as assessed by the 
investigator, with the parent study pr otocol requirements.

Novartis Confidential Page 13
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Exclusion criteria Patient has been permanently discontinued from panobinostat study treatment in 
the parent study due to unacceptable toxicity, non -compliance to study procedures, 
withdrawal of consent or any other reason.
Patient has participated in a Novartis sponsored combination trial where 
panobinostat was dispensed in combination with another study medication and is 
still receiving combination therapy. 
Investigational therapy Panobinostat 5 mg, 10mg, 15mg and/or 20 m g capsules, dose and dose regimen 
depending on parent protocol
Efficacy assessments At every quarterly visit, the investigator is required to confirm that the patient 
continues to have clinical benefit and may continue receiving study treatment.
Safety assessments Adverse events and SAEs will be collected continuously moving forward. 
Other assessments Not applicable.
Data analysis Proportion of patients with clinical benefit as assessed by the investigator will be 
summarized at scheduled visits. The a ssessment of safety will be based mainly on 
the frequency of AEs and SAEs .As needed, safety information on patients from 
this protocol will link to the patient identifiers from the parent protocol.
Key words Panobinostat roll-over study for continued use of panobinostat to patients receiving 
panobinostat in a Novartis -sponsored Oncology OGD&GMA study which has 
reached its objectives and who are benefiting from treatment with panobinostat .

Novartis Confidential Page 14
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Global changes in the epigenetic landscape are a hallmark of cancer ( Jones et al 2007 ). Recent 
advancements in the rapidly  evolving field of canc er epigenetics have shown extensive 
reprogramming of every component of the epigenetic machinery  in cancer including DNA 
methy lation, histone modifications, nucleosome positioning and non- coding RNAs, 
specificall y microRNA expression (Boumber et al 2011 ). The reversible nature of epigenetic 
aberrations has led to the emergence of the promising field of epigenetic therap y, which is 
alread y making progress with the recent FDA approval of 
four epigenetic drugs for cancer 
treatment: two DNA methy ltransferase inhibitors, azacitidine (Vidaza®) and decitabine 
(Dacogen®), followed by two histone deacet ylase inhibito rs (DACis), vorinostat (Zolinza®) 
and romidepsin (Istodax®). So far all four FDA approved epigenetic drugs have shown the 
greatest efficacy  in hematopoietic malignancies, i.e. azacitidine and decitabine in 
myelodysplastic disorders and leukemia ( Issa et al 2006 ; Kantarjian et al 2006 ; Issa 2007 ) and 
vorinostat and romidepsin in cutaneous T
-cell lymphoma (CTCL ) (Duvic et al 2007 ; Grant et 
al 2010 ). General features of responses observed with these agents have included the 
requirement for multiple cycles of therapy , a slow onset of response with some patients 
experiencing a long -lasting clinical benefit requiring prolonged treatment administration.
Similar observations have 
been made in clinical trials with other investigational DAC 
inhibitors, including panobinostat ( Prince et al 2009 ; Duvic et al 2012 ; Younes et al 2012 ). In 
these cases the question has been raised on how to continue treatment of few patients beyond 
study  completion and assure adequate monitoring and proper regulatory  reporting 
of relevant 
safet y information. In order to allow continued access to a given anticancer therapy  to patients 
benefiting from their study  treatment, a roll-over study  design has been wide ly used. 
Currently  there are 37 roll-over study  protocols posted on clinicaltrials.gov for the treatment 
of patients with various malignancies (clinicaltrials.gov).
The purpose of this study  is to allow continued use of oral panobinostat in patients who are 
currentl y receiving single agent (s.a) panobinostat treatment in a Novartis -sponsored, 
Oncology  Global Development & Global Medical Affairs (OGD&GMA) study  that has 
reached its objectives, are not progressing on the current study  treatment as defined by the 
parent protocol and are benefiting from the treatment as judged b y the investigator .
This roll-over study  is designed to accept patients with various disease origins. Please refer to 
the parent protocol for the disease background information and ration ale for use of 
panobinostat in their individual indications.

Novartis Confidential Page 15
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of panobinostat
Panobinostat (LBH589) belongs to a structurall y novel cinnamic hydroxamic acid class of 
compound s and is a pan-inhibitor of Class I, II and IV histone deacety lases (HDACs). 
HDACs are involved in the deacet ylation of histone and non- histone cellular proteins, 
targeting lysine groups on chromatin and transcription factors and various non- histone 
protei ns such as p53, tubulin, heat shock protein 90 (Hsp90), and retinoblastoma protein (Rb). 
Panobinostat has shown antitumor activity  in preclinical models and in cancer patients and 
has been formulated as an oral capsule and as a solution for intravenous (i.v.) injection. Both 
the i.v. and the oral formulations have been investigated in Phase IB/II studies in advanced 
solid tumors and hematological malignancies.
1.2.1.1 Non-clinical experience
Panobinostat has been developed as an anticancer agent based on its potent ial to act:
by exhibiting differential antiproliferative activity  against a broad range of solid tumors 
cell lines and high sensitivity  in ly mphomas and hematologic malignancies cell lines, 
including acute m yeloid leukemia (AML) and multiple my eloma (MM) .
by inducing consistent tumor growth control in various tumor -bearing xenografted mice 
and by  increasing histone -H3 and -H4 acety lation in excised tumors .
by showing s ynergistic or additive anti -tumor effect in combination with other anti -cancer 
agents such as trastuzumab, docetaxel, bortezomib or standard cy totoxic agents e.g., 
doxorubicin, fludarabine, Ara- C.
The potent anticancer effects of panobinostat seen in experimental models may result from 
two distinct mechanisms of action, both related to pan-HDAC inhibition. Panobinostat was 
shown to affect epigenetic mechanisms of gene expression via inhibition of Class I HDACs, 
as shown by induction of histone acetylation and consequent induction of cell cycle control 
genes (i.e. p21) and to inhibit HDAC6 through abrogation of Hsp90 –mediated stabilization of 
client oncoproteins, resulting in their depletion and in reduced downstream oncogenic 
signaling (Atadja 2011 ). Although the pharmacody namic effects of panobinostat on histone 
acetylation have been consistently  seen in experimental models as well as in cancer patients, 
histone hy peracety lation does not seem to relate with therapeutic activity . Similar results have 
been reported for other HDAC inhibitors and thus clinical development of these agents has 
been broadly  approached by  targeting various hematologic and non -hematologic malignancies 
(Atadja 2009 , Atadja 2011 , Boumber et al 2011 ).
For the latest information on the pre-clinical pharmacology  and toxicology  of panobinostat, 
please refer to the current [Investigator Brochure].
1.2.1.2 Clinical experience
As of 31 December 2011, 35 clinical studies, including clinical pharmacology  (CP), Phase I 
and Phase II trials, as well as two randomized Phase III studies have either been completed or 
are ongoing. Safet y risks associated with panobinostat have been character ized in more than 

Novartis Confidential Page 16
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
2000 patients enrolled in the overall clinical development program. The majority  of severe 
adverse events is hematologic (mainl y thrombocy topenia), easily documented with routine 
hematology  tests and manageable with conventional supportiv e care and dosing modifications. 
Common non-hematologic toxicities, including gastro -intestinal (GI) toxicity  and fatigue, are 
mild to moderate in severity  and generall y reversible. They  are manageable with dose 
adjustments. The most common ECG findings include post-baseline increase in frequency  of 
sinus tachy cardia, T-waves changes as well as depressed ST segment. They  can be readily 
captured by conventional non-invasive cardiac monitoring (ECGs) and do not appear to be 
clinically  significant. With the in termittent oral dosing schedules (three -times -a-week, weekly 
or every  other week) used in current clinical trials, QTcF above 500 msec is uncommon 
(6/635 patients, 0.9%) and noted only with the weekl y oral dosing regimen. No torsade de 
pointes has been rep orted in clinical trials with oral panobinostat.
The efficacy  and safet y of panobinostat in combination with bortezomib and dexamethasone 
were evaluated in a randomised, double -blind, placebo -controlled, multicentre phase III study 
in patients with relapse d or relapsed and refractory  multiple myeloma who had received 1-3 
prior lines of therapies.
Patients received panobinostat (20 mg taken orally  once a day, three times per week, on a 2 
weeks on and 1 week off dosing regimen), in combination with bortezomib (1.3 mg/m2 
injected intravenousl y) and dexamethasone (20 mg). Treatment was administered for a 
maximum of 16 cycles. A total of 768 patients were randomised to either the panobinostat + 
bortezomib + dexamethasone (n=387) or the placebo + bortezomib + dexa methasone (n=381) 
arm. Demographics and baseline disease characteristics were balanced and comparable 
between the stud y arms. 
The median PFS (95% CI) was 12.0 months (10.3, 12.9) and 8.1 months (7.6, 9.2), 
respectivel y. Out of the pre-specified subgroup of patients with prior treatment with 
bortezomib and an immunomodulatory  agent (N=193), 76% of patients had received at least 
two prior regimens. The median PFS (95% CI) was 12.5 months (7.26, 14.03) in the 
panobinostat + bortezomib + dexamethasone arm and 4.7 months (3.71, 6.05) in the placebo + 
bortezomib + and dexamethasone arm [HR: 0.47 (0.31, 0.72)]. 
Regarding safet y, the median duration of exposure in the study  was 5.0 months. 15.7% of 
patients were exposed to study  treatment for ≥48 weeks. The most common non-
haematological adverse reactions were diarrhoea, fatigue, nausea and vomiting. Treatment -
emergent haematological toxicities included thrombocy topenia, anaemia, neutropenia and 
lymphopenia. QTcF >480 and <500 msec was recorded in 1.3% of patients and change from 
baseline of >60 msec was observed in 0.8% of patients. No patient had an absolute 
QTcF >500 msec.
1.2.1.2.1 Clinical pharmacokinetics and pharmacodynamics
Single agent oral panobinostat is administered three -times -a-week (TI W) every -week (QW) or 
every-other -week (QOW). Following oral administration, panobinostat is rapidly  absorbed 
with peak plasma concentrations reached within 1 hour; systemic clearance is 33 L/hour and 
central volume of distribution 25 liters. Half-life associated with the distribu tion, initial 
elimination and terminal elimination phase based on population parameterization are 0.15, 2.3 

Novartis Confidential Page 17
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
and 37 hours, respectively. Observed drug accumulation is approximately  1.14 fold with TIW 
schedule. This is consistent with an effective half-life of 15 hours. Absolute oral 
bioavailability  is 21%.
The extent of binding to human plasma protein is moderate (89.6%) in vitro and independent 
of panobinostat concentration. Panobinostat can be administered without regard to food 
(Shapiro et al 2012 ).
Panobinostat is extensively  metabolized in patients, with the parent compound accounting for 
6-9% of the drug-related exposure in plasma with the remainder accounted for by 
approximately  40 metabolites. Metab olites formed via the primary  metabolic pathway s were 
all inactive for DAC inhibitory  activity  in vitro .
CYP3A4 is the main oxidative metabolizing enzyme of panobinostat with minor involvement 
of CYP2D6 and CYP2C19. Drug -drug interaction (DDI) studies in cancer patients using 
standard drug probes have shown a weak interaction between panobinostat and a strong 
CYP3A inhibitor (ketoconazole) (Hamberg et al 2011 ) or between panobinostat and a 
sensitive CYP2D 6 substrate (dextromethorphan). In both cases the systemic exposures of 
panobinostat in the presence of ketoconazole or the s ystemic exposure of dextromethorphan in 
the presence of panobinostat increased by 80% and 60%, 
respectively . Therefore co-
administr ation of a strong CYP3A inhibitor or of a sensitive CYP2D6 substrate with 
panobinostat is feasible when medically  necessary  with close monitoring. Based on the results 
of the ketoconazole DDI study , oxidative metabolism via CYP enzyme is a minor metabolic 
pathway  of panobinostat, suggesting no relevant clinical PK interaction via CYP pathway s.
Based on in vitro and clinical metabolic profile of panobinostat and in-silico prediction, co-
administration of panobinostat with a strong CYP3A4 inducer, rifampicin is expected to 
decrease panobinostat systemic exposure by 70% in patients. Co-administration of 
panobinostat with strong CYP3A inducers is to be avoided.
For further details, please refer to the current panobinostat [Investigator Brochure] .
2 Rationale
2.1 Stud yrationale and purpose
In various clinical trials with single agent (s.a.) oral panobinostat, it was evident that some 
patients may benefit from prolonged treatment with this agent well beyond the study 
objectives have been attained (Prince et al 2009 ; Duvic et al 2012 ; Younes et al 2012 ). 
Recognizing that it is important to allow these patients to continue their therap y under a 
controlled, even if less frequent monitoring plan, this multi -center, open -label roll-over 
protocol has been designed to better characterize the long-term safety  of s.a. oral 
panobinostat inpatients being treated in a Novarti s
-sponsored, Oncology  OGD&GMA study 
who are responding to treatment with this agent.
The purpose of this study  is to better characterize the long-term safety of panobinostat in 
patients who are on s.a. panobinostat treatment in a Novartis -sponsored, Oncolo gy 
OGD&GMA study  that has reached its objectives, who are not progressing on the current 
study  treatment as defined by the parent protocol and are benefiting from this treatment as 

Novartis Confidential Page 18
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
judged by the investigator . Parent studies eligible to participate in the roll-over study  will be 
decided by Novartis. Investigator initiated trials (IITs) will not be included. The objectives of 
the parent study  must have been reached and the parent study  must be in the process of being 
completed and reported.
Patients enrolled in this study  will continue to receive s.a. oral panobinostat until one of the 
following occurs: the patient is no longer benefiting from the treatment (e.g. the underl ying 
disease is progressing), unacceptable toxicity  develops, consent is withdrawn, non -compliance 
with the protocol, the investigator feels it is no longer in the patient’s best interest to continue 
therap y (e.g. pregnancy, etc.), or the patient’s death.
2.2 Rationale for the study  design
This is a multi -center, open -label study to better characterize the long-term safety  of s.a. oral 
panobinostat inpatients being treated in a current Novartis -sponsored, Oncology  OGD&GMA
study , who are benefiting from the treatment with oralpanobinostat.
The design of this roll -over study  is widel y used in cancer clinical programs to allow access to 
an effective study  treatment to those patients who are benefiting from this therapy  well 
beyond trial objectives completion. The study  protocol is also designed to gather long-term 
safet y inform ation in cancer patients who are eligible to transfer into this roll-over study . The 
well-known safet y profile of panobinostat supports the rationale for a less frequent visit 
schedule more adapted to standard of care practice with monitoring focused on ad verse events 
reporting. This will ensure not only adequate supervision of the patients’ well-being but also 
proper regulatory  reporting of relevant safet y information.
2.3 Rationale for dose and regimen selection
The dose/s and regimen/s provided in this roll-over study  protocol are those defined in the 
parent protocols for each enrolled patient. Therefore, depending on the capsule strength/s used 
in the parent protocol, s.a. panobinostat will be provided as 5-mg and/or 20-mg hard gelatin 
capsules. At the time of transition to the roll-over study , the starting dose and regimen of oral 
panobinostat should be the same as the last assigned dose and regimen that were given in the 
parent study . Dosing modifications thereafter (following the starting dose) may  be done at the 
discretion of the investigator based upon what is in the patient’s best interest.
2.4 Rationale for choice of combination drugs
Not applicable.
2.5 Rationale for choice of comparators drugs 
Not applicable. 
2.6 Risks and benefits 
Based on the last edition ofthe IB, the risk/benefit assessment of panobinostat (LBH589) is 
considered favorable and unchanged. The risks of single agent panobinostat are well 
characterized by a large safet y database and no significant new safet y signals have emerged 
since previous editions of this IB. This assessment serves as a basis for the safety  monitoring 

Novartis Confidential Page 19
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
of panobinostat tested in combination with other cancer agents in ongoing clinical studies. As 
appropriate, monitoring of patients is required in the clinical development protocols and no 
protocol changes have been or are planned to be made. Management of adverse events 
remains confined to clinical monitoring per protocol and appropriate dose and schedule 
modifications with supportive care as clinically  indicated.
Consistent with the safety  profile from the extensive experience with panobinostat single 
agent studies, the major toxicities associated with the active combination of panobinostat with 
bortezomib and dexamethasone in MM patients involved the same adverse events noted 
during single agent treatment. However, the overlapping toxicity , primarily  hematologic, GI 
and constitutional in nature was apparent with respect to frequency  and severit y due to the 
combination regimen. Cardiac toxicity  was unremarkable. The known toxici ties could be 
predicted and could be effectivel y managed with established clinical interventions. In the 
context of the significant clinical benefit panobinostat provides to MM patients with limited 
treatment options, its tolerability  is considered accepta ble.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3 -1below.

Novartis Confidential Page 20
Amended Protocol Version 01 C lean Protocol No. CLBH589B2402B
Table 3-1 Objectives and related endpoints
Objective Endpoint Analysis
Primary Refer to Section 10.4
To eval uate long term safety data ( SAEs and 
AEs)Frequenc y and severity of AEs/SAEs
Secondary Refer to Section 10.5.2
To evaluate clinical benefit as assessed by the 
investigatorProportion of patients with clinical benefit as 
assessed by the investigator at scheduled visits

Novartis Confidential Page 21
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
4 Study  design
4.1 Description of study  design
This is a multi- center, open -label study  to better characterize the long-term safety  of s.a. oral 
panobinostat to in patients being treated in current Novartis -sponsored, Oncology 
OGD&GMA study  and who are benefiting from the treatment with s.a. oral pano binostat as 
determined by the guidelines of the parent protocol (for which the study objectives have been 
met) and based on the investigator’s clinical judgment.
This roll-over study  will not include screening period as patients will transfer directly  from
the parent study  and commence with panobinostat as soon as they are consented and meet 
inclusion criteria of the roll-over protocol. All patients must report to the study  site for their 
first visit and commence study  participation. At that time, a quarter ly (12 +/- 2 weeks) suppl y 
of oral panobinostat willbe dispensed to the patient or as per local practice.
Patients must return to the study  center on a quarterl y (every  12 +/- 2 weeks) basis for 
resupply  of study  medication at which time limited drug dispensing information will be 
collected. C hanges in dosing which might occur any time during the study  treatment will be 
documented on the dose administration page.
Patients may return to the study  center more frequentl y at the physicians’ discretion as 
clinically  indicated or as per standard of care, however, these unscheduled visits will not be 
captured in the eCRF, but rather onl y in the source documents at the stud y center.
All adverse events and serious adverse events will be collected throughout the study . 
Patients entering the roll-over protocol should be followed at the investigator’s discretion for 
known and/or clinicall y notable AEs that occur on panobinostat treatment as described in the 
current version of the [Investigator Brochure] .
Patients will continue to be treated in the roll -over protocol until they  are no longer benefiting 
from the s.a. oral panobinostat treatment, develop unacceptable toxicities, withdraw consent, 
are non-compliant to the protocol, the investigator feels it isno longer in the patient’s best 
interest to continue s.a. oral panobinostat therapy , pregnancy  occurs or the patient dies, or 
study  is terminated by sponsor , whichever comes first. At every  quarterl y visit, the 
investigator is required to confirm that thepatient continues to have clinical benefit and may 
continue receiving stud y treatment.
A patient will reach the end of the study  treatment when s.a. oral panobinostat treatment is 
permanentl y discontinued. A 30-day safety follow - up after last dose of study drug should be 
conducted.
The study  is expected to remain open for 5 years or until such time that enrolled patients no 
longer need treatment with panobinostat, whichever occurs earlier.

Novartis Confidential Page 22
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Figure 4-1 Study  design
4.2 Timing of interim analy ses and design adaptations
No interim anal yses are planned.
4.3 Definition of end of study
End of study  is defined as either a 5 year duration or when all patients in this study  have 
permanentl y discontinued panobinostat treatment and the end of treatment visit plus the 30-
day safety follow up have 
been performed for each patient (and no further follow -up is 
needed), whichever comes earlier.
4.4 Early study  termination
The study  can be terminated at any time for any  reason by  Novartis. Should this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described inSection 7.1.3 The investigator may be informed of additional procedures to be 
followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial.
5 Population
5.1 Patient population
The study  population is constituted of patients with various 
malignancies who participated in 
a Novartis -sponsored, Oncology  OGD&GMA clinical trial for their specific indication and 
qualify  to transfer to this roll -over protoc ol.
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study.
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all ofthe following criteria:
1.Patient is currently
 enrolled in a Novartis -sponsored, Oncology  OGD&GMA study  
receiving s.a. oral panobinostat and has fulfilled all their requirements in the parent stud y.
2.Patient is currently  benefiting from the treatment with s.
a. oral panobinostat as determined 
by the guidelines of the parent protocol and according to the Investigator’s clinical 
judgment.

Novartis Confidential Page 23
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
3.Patient has demonstrated compliance, as assessed by  the investigator, with the parent 
study  protocol requirements.
4.Willingness and ability  to comply  with scheduled visits, treatment plans and any other 
study  procedures.
5.Written informed consent obtained prior to enrolling into the roll -over study .
If consent cannot be expressed in writing, it must be formall y documente d and 
witnessed, ideall y via an independent trusted witness.
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Patient has been permanently  discontinued from s.a. oral panobinostat study  treatment in 
the parent study  due to unacceptable toxicity , withdrawal of consent, non -compliance to 
study  procedures or an y other reason (including progression of disease).
2. Patient has participated in a Novartis sponsored combination trial where panobinostat was 
dispensed in c ombination with another study  medication and is still receiving combination 
therap y.
3.Patient is pregnant or nursing (lactating) at time of entry  into the roll -over protocol. 
Pregnancy  is defined as the state of a female after conception and until the termi nation of 
gestation, confirmed b y a positive hCG laboratory test.
4.Women of child-bearing potential and male patients with sexual partner(s) of child-
bearing potential unwilling to use highl y effective methods of contraception during dosing 
and for a specif ied duration ( 6 months for male participants and 3 months for females) 
after stopping study  treatment.
Highly effective contraception methods include :
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception .
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment . In
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level assessment .
Male sterilization (at least 6 m onths prior to enrolling ).For female patient son the 
study  the vasectomized male partner shoul d be the sole partner for that patient .
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of horm onal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception. Women using hormonal 
contraceptives should additionally  use a barrier method of contraception. 
Note: In case of use of oral contraception, women should have been stable on the same pill 
for a minimum of 3 months before entering the roll- over protocol. 
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontan
eous) amenorrhea with an appropriate clinical 

Novartis Confidential Page 24
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
profile (i.e. age appropriate, history  of vasomotor symptoms) or have had surgical 
bilateral oophorectom y (with or without hysterectomy ), total hysterectomy , or tubal 
ligation at least six weeks ago. In the case of oophorectom y alone, only  when the 
reproductive status of the woman has been confirmed by follow up hormone level 
assessment is she considered not of child bearing potential. 
If a study  patient becomes pregnant or suspects being pregnant during the study  or 
within 30days after the final dose of panobinostat , the Investigator/ Study  Doctor 
need s to be informed immediately  and ongoing study  treatment with panobinostat has 
to be stopped immediately.
5.Sexually  active males unless they  use a condom during intercourse while ta king the drug 
during treatment and for 6 months after stopping treatment and should not father a child in 
this period. A condom is required to be used also by vasectomized men as well as during 
intercours e with a male partner in order to prevent delivery  of the drug via semen.
6 Treatment
6.1 Stud y treatment
Study  drug and investigational treatment refer to s.a. oral panobinostat (hereof defined as the 
study  treatment).
6.1.1 Dosing regimen
Table 6-1 Dose and treatment schedule
Study treatments Pharmaceutical form and 
route of administrationStrength Dosing Regimen
Panobinostat Capsule for oral use 5 mg, 10mg, 15mg and/or 
20 mg depending on 
parent protocolPer parent protocol
The dose/s and regimen/s provided in this roll-over study  protocol are those defined in the 
parent protocols for each enrolled patient, hence this may differ for patients enrolling from 
various studies.
Panobinostat will initially  be provided as 5 mg and/or 20 mg hard gelatin capsules, depending 
on the strength/s used in the parent protocol. If the need arises at a later time, also 10mg 
and/or 15mg capsules might be used. The investigational treatment is to be stored in a secure 
locked area while under the responsibility  of the investigator. Receipt and dispensing of 
investigational treatment must be recorded b y an authorized person at the investigator’s site.
Patients will be instructed to take panobinost at orally  with a glass of water, at the last assigned
dose and schedule received in the parent protocol, either consistently  with food or consistently  
without food. The capsule should be swallowed as a whole and should not be chewed or 
crushed. Dietary  habits at the time of enrolling in the study  from the parent study  should be 
kept as consistent as possible throughout the stud y.

Novartis Confidential Page 25
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
6.1.2 Ancillary  treatments
Not applicable
6.1.3 Rescue medication
Not applicable
6.1.4 Guidelines for continuation of treatment 
The starting dose of oral panobinostat should be the same as the lastassigned dose and 
schedule that was given in the parent study .Assigned dose is the dose as designated by 
investigator and does not include unintended changes or error in dosing in parent protocol.
Dose modification thereafter (following the starting dose) may  be done at the discretion of the 
investigator based upon what is in the patient’s best interest.
In case patients do not tolerate the dosing schedule, dose adjustments are permitted in order to 
keep the patient on studydrug. These dose adjustments may be delays in dosing and/or 
reductions in the dose being administered. Dosing should alway s be temporaril y discontinued 
if the physician determines it is in the best interest of the patient. All dose modifications 
should be recorded in the source documents and on the Dosage Administration Record Form.
Patients receiving a reduced dose of panobinostat due to toxicity who are clearl y benefiting 
from panobinostat and whose AE(s) remain grade < or = 1, which the patient believes is/are 
tolerable may at the discretion of the Investigator after agreement by  the Sponsor return to the 
initial dosage in 5mg/increments. Dose re-escalation should be reviewed on a case basis and 
requires agreement between Sponsor andInvestigator. No more than 2 dose reductions are 
permitted (i.e. the minimum dose patients may  receive is 5 mg/day ).
6.1.5 Treatment duration
Patients will continue to be treated until they are no longer benefiting from s.a. oral 
panobinostat, develop unaccepta ble toxicities, withdraw consent, are non-compliant with the 
protocol, the investigator feels it is no longer in the patient’s best interest to continue 
panobinostat therap y (e.g. disease progression, pregnancy , etc.) or the patient dies, whichever 
comes first. A patient will reach the end of the roll-over study  when panobinostat is 
permanentl y discontinued. A 30-day safety follow - up should be conducted after the last dose 
of panobinostat. At every quarterl y visit, the investigator is required to confirm th at the patient 
continues to have clinical benefit and may  continue receiving study  treatment.   
The study  is expected to remain open for 5 years or until such time that enrolled patients no 
longer need treatment with s.a. oral panobinostat , whichever occurs first. The study  can be 
terminated at an y time for an y reason b y Novartis.
6.1.6 Starting dose rationale
The starting dose of panobinostat should be the same as the last dose that was given in the 
parent stud y. After this, the dose of panobinostat is based on the investigator’s judgment .

Novartis Confidential Page 26
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
6.2 Dose modifications 
For patients who do not tolerate the specified dose, dose adjustments are permitted in order to 
allow the patient to continue treatment. The following guidelines should be applied.
If a patient requires a dose delay  more than 28 days from the intended day of the next 
scheduled dose, the patient should be considered for discontinuation of treatment. I f, however, 
the patient was clearly benefitting from treatment and the cause of the delay has resolved, the 
patient may be able to restart treatment after discussion with Novartis. This option should be 
used with the highest amount of caution keeping the safet y of the patient in mind, and 
evaluating whether or not the benefit outweighs the risk. 
6.2.1 Non
-Cardiac Toxicity Dose Modifications
Treatment dose and/or schedule modification may be required based on individual tolerability . 
Clinical judgment on how to continue the treatment should be exercised when a patient 
experiences adverse drug reac tions. 
If a dose reduction is required, the dose of panobinostat should b e reduced by  decrements of 5 
mg(i.e. from 20 to 15 mgor from 15 to 10 mg). The dose should not be reduced below 10 mg 
daily and the same treatment schedule should be maintained. 
6.2.2 Thrombocytopenia 
If patients experience thrombocy topenia (TCP), panobinostat may need to be temporaril y 
withheld and the subsequent dose may need to be reduced. In patients with Common 
Terminology  Criteria for Adverse Events version 3.0 (CTCAE) grade 3 (<50x109/L, 
complicated by bleeding), or grade 4 (<25x109/L) thrombocy topenia, panobinostat therap y 
should be withheld and resumed at a reduced dose upon recovery  to ≤ grade 2 (≥50x109/L). 
Discontinuation of treatment may be considered if thrombocy topenia does not improve 
despite the treatment modifications described above and/or the patient requires repeated 
platelet transfusions. 

Novartis Confidential Page 27
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Table 6-2 Thrombocy topenia dose modifications
Thrombocytopenia grade on 
day of treatment Modification of panobinostat 
starting dose Panobinostat dose on 
recovery to ≤ grade 2 
thrombocytopenia ( ≥50 x 
109/L) 
Grade 3 with bleeding 
Platelets <50 x 109/L Omit dose Resume at reduced dose 
Grade 4 
Platelets <25 x 109/LOmit dose Resume at reduced dose 
6.2.3 Gastrointestinal toxicity  
Gastrointestinal toxicity  is very common in patients treated with panobinostat. Patients who 
experience diarrhea and nausea or vomiting may require temporary  dose disconti nuation or 
dose reduction. 
Table 6-3 Diarrhea dose modifications
Adverse drug 
reaction Grade on day of 
treatment Modification of 
panobinostat starting 
dose Panobinostat dose on 
recovery to ≤ grade 1 
Diarrhoea Grade 2 despite anti -
diarrheal medicinal 
product Omit dose Resume at the same 
dose 
Grade 3 despite anti -
diarrheal medicinal 
product Omit dose Resume at reduced 
dose 
Grade 4 despite anti -
diarrheal medicinal 
product Discontinue Discontinue 
At the first sign of abdominal cramping, loose stools, or onset of diarrhea, it is recommended 
that the patient be treated with anti-diarrheal medication (e.g. loperamide). Prophy lactic anti-
emetics should be administered at the discretion of the phy sician and in accordance with local 
medical practice.
6.2.4 Neutropenia 
Neutropenia may  require temporary  or permanent dose reduction.
Table 6-4 Neutropenia dose modifications
Neutropenia grade on day of 
treatment Modification of panobinostat 
starting dose Panobinostat dose on 
recovery to grade 2 
neutropenia (<1.5 -1.0 x 109/L) 
Grade 3 neutropenia (<1.0 -0.5 x 
109/L) Omit dose Resume at same dose 
Grade 4 neutropenia (<0.5 x 
109/L) or febrile neutropenia 
(<1.0 x 109/L and fever ≥38.5°C) Omit dose Resume at reduced dose 

Novartis Confidential Page 28
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
In case of grade 3 or 4 neutropenia, physicians should consider the use of growth factors (e.g. 
G-CSF) according to local guidelines. Discontinuation of treatment may be considered if 
neutropenia does not improve despite the dose modifications and/or despite the addition of 
colony stimulating factor therap y according to local medical practice and treatment guidelines, 
and/or in case of severe secondary  infections. 
6.2.5 Follow-up for to xicities
Patients who treatment is interrupted or permanently  discontinued from study  treatment due to 
an AE or abnormal laboratory  value should be followed at least once a week during drug hold 
and be followed for 4 weeks, and subsequently  at 4-week intervals, until resolution or 
stabilization of the event, whichever comes first. All patients will be followed for AEs and 
SAEs for 30 day s following the last dose of panobinostat. 
6.2.6 Dose modification of panobinostat for prolonged QTcF interval
All cardiac events should be treated as per the local standard of care and referred to a 
cardiologist if clinically indicated. The central and/or local readings of ECGs will use the 
Fridericia correction for QTc interval assessment: QTcF. Any final decisions concernin g 
panobinosta t dose modifications or permanently  discontinuing the patient from study 
treatment due to QTcF prolongation will be based on the assessment performed by the 
Investigator. 
In case of average QTcF > 450 ms pre
-dose:
Assess the quality  of the ECG recording a nd the QT value and repeat if needed
Do not initiate study  treatment
Determine the serum electroly te levels (in particular hy pokalemia, hy pomagnesemia). If 
abnormal, correct abnormalities before initiating study  treatment. 
Review concomitant medication use for other causes for QT prolongation, and for drugs 
with the potential to increase the risk of drug exposure related QT prolongation (e.g 
concomitant use of strong CYP3A4 inhibitors)
Within 7 day s, repeat triplicate pre- dose ECG if average QTcF > 450 ms, do not initiate 
study  treatment
If average QTcF ≤ 450 ms, initiate study  treatment.
In case of average QTcF > 480 ms, (or average QTcF prolongation >60 ms from baseline) any 
time after firstdose of panobinostat until end of panobinostat treatment:
Assess the quality  of the ECG recording and the QT value and repeat if needed.
Interrupt panobinostat treatment
Determine the serum electroly te levels (in particular hy pokalemia, hy pomagnesemia). If 
abnormal, correct abnormalities before resuming study  drug t reatment. 
Review concomitant medication use for other causes of QT prolongation, and for drugs 
with the potential to increase the risk of drug exposure related QT prolongation.
Check study  drug dosing schedule and treatment compliance
Consider more freque nt ECG monitoring (e.g. approximately  every  2-3 hours between 2 
hours post treatment and 6 hours post treatment) until average QTcF is ≤ 480 ms)

Novartis Confidential Page 29
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
After confirming ECG reading at site, if average QTcF > 480 ms: 
Interrupt panobinostat treatment
Repeat ECG and confirm ECG diagnosis by  a cardiologist 
If average QTcF confirmed > 480 ms:
Correct electrol ytes, eliminate culprit concomitant treatments, and identify  clinical 
conditions that could potentially  prolong the QT 
Consult with a cardiologist (or qualified specialist)
Increase cardiac monitoring as indicated (e.g., perform approximately  hourly  ECGs at 
between 2h post dose of 6h post dose on the same day  an average QTcF > 480 ms is 
reported and pre -dose and at 2h post dose and the next dosing day s) until the average 
QTcF returns to ≤ 480 ms
After resolution within 7 day s to ≤ 480 ms, consider re -introducing panobinostat treatment 
at the same or reduced dose, and increase ECG monitoring (e.g., pre -dose panobinostat 
and 2h post panobinostat) for the next treatments:
If average QTcF remains ≤ 480 ms, continue planned ECG monitoring during subsequent 
panobinostat treatment. 
If average QTcF recurs > 480 ms after re -introduction of panobinostat treatment or 
remains > 480 ms for more than 7 day s prior to re -introduc tion, discontinue patient from 
study  treatment. 
Please note that for unscheduled ECGs at an y time during panobinostat treatment: 
If a single QTcF is > 480 ms, two additional ECGs should be performed. The three ECGs 
should be separated b y 5-10 minutes. The average QTcF of those three ECGs should be 
calculated and used for determination of panobinostat dose modifications. 
6.2.7 Suggested management of selected adverse events
One of the most common adverse events associated with treatment with oral panobinostat is 
reversible thrombocy topenia; the degree of thrombocy topenia is dose-dependent. Other side 
effects include fatigue (dose -dependent), nausea, vomiting and diarrhea.
Diarrhea is especially  problematic since, when more severe, can affect drug exposure and 
result in patient discontinuation. Diarrhea can be controlled with the following regimen which 
includes of the use of loperamide. 
Patient should be instructed to contact ph ysician at the onset of diarrhea
Patient should be encouraged to maintain adequate o ral hydration (at least 240 m levery  2 
hours) with the onset of diarrhea.
The patient should be instructed to have loperamide readil y available and to begin 
treatment for diarrhea at the first episode of poorly formed or loose stools or the earliest 
onset of bowel movements more frequent than normally expected for the patient.
Loperamide 4 mg should be taken at the first loose stool or more frequent than usual 
bowel movements, followed by 2 mg as needed, no more frequently than every 4 hours, 
not to exceed a total of 16 mg in 24 hours. 

Novartis Confidential Page 30
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Patients with diarrhea ≥ grade 2 despite this loperamide regimen should interrupt 
treatment with panobinostat as described in Table 6 -3.
If the above regimen is inadequate t hen additional evaluation and treatment should be 
pursued as medically  indicated. 
Replacement i.v. fluids and electrol ytes may  be used as appropriate.
Additional treatment should be provided in accordance with institutional standard of care 
and/or local g uidelines.
Premedication with loperamide is not recommended. 
The use of drugs with laxative properties should be avoided because of the potential for 
exacerbation of diarrhea. Patients should be advised to contact their ph ysician to discuss 
any laxative u se.
For orally administered panobinostat, 
no grade 4 QTc has been reported with “interrupted” 
dosing schedules. For oral dose of 20 mg or 60 mg given three times weekly , the incidence of 
grade 3 QTc prolongation ranges from <1% to 6%. The largest QTc chang e is seen 
approximately  five day s after the drug is given and does not correlate with drug serum levels. 
For detailed safety  information as well as the list of adverse drug reactions (i.e. those AEs 
considered causall y related to panobinostat), please ref er to the latest panobinostat IB. 
6.2.8 Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events. 
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal AL T and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N 
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], combined with [TBIL > 2 x 
baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as ALP elevation > 2.0 x ULN with R value < 2 in patients without bone metastasis, or 
elevation of ALP liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  dividing the ALT by  the ALP, using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably  within 48 hours from 
the awareness of the abnormal results. The evaluation should include labora tory tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 

Novartis Confidential Page 31
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect biliru bin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 
2.A detailed history , including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-existing liver 
conditions or risk factors, should be collected. 
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary  
tract) may  be warranted. 
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK analy sis is 
performed in the stud y. 
5.Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist. 
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
signific ant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term “potential drug -induced liver injury ”. All events should be followed up with the outcome 
clearl y documented.
6.3 Concomitant medi cations
All medications and significant non-drug therapies (including physical therap y and blood or 
platelet transfusions) administered at the time of entry  into this rollover protocol through 30 
days after the last panobinostat dosing and the reasons for therap y use should be reported in 
the source documents at the study  center. Medications include not only physician prescribed 
medications, but also all over-the-counter medications, vitamins, herbals and alternative 
therapies.
The following restrictions apply  during the study :
No other investigationl therap y should be given to patients.
No anticancer agents other than the stud y medication (panobinostat) should be given to 
patients during the stud y. If such agents are required for a patient then the patient must 
first be withdrawn from the study .
The following recommendations should be followed for the use of medications that may 
affect or may  be affected by  panobinostat treatment:
For patients who require chronic anticoagulant therap y while on panobinostat therap y, low 
molecular weight heparin (L MWH) should be the preferred anticoagulant medication. In 
patients for whom low molecular weight heparin use is to be initiated, the degree of 
thrombocy topenia should be considered, coagulation parameters monitored, and dose of 
anti-coagulant adjusted accordingl y.

Novartis Confidential Page 32
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Concomitant use of strong CYP3A4/5 inhibitors (including, but not limited to , 
ketoconazole, itraconazole, ritonavir, clarithromycin and telithrom ycin) should be avoided. 
If medicall y necessary , close clinical monitor ing of signs and s ymptoms of panobinostat 
related AEs is recommended when long
-term ( ≥ 1 week) concomitant administration of 
any strong CYP3A inhibitors occurs, as this may  increase the exposure of panobinostat. 
Co-administration of panobinostat with a moderate or weak CYP3A inhibitor is allowed. 
Star fruit, pomegranates or pomegranate juice, grapefruit juice that are known to inhibit 
CYP3A should be avoided during treatment with panobinostat. In patients with hepatic 
impairment receiving concomitant medici nal products which are strong CYP3A4 
inhibitors, treatment with panobinostat should be avoided due to lack of experience and 
safet y data in this patient population. 
In silico data showed that the systemic exposure of panobinostat may be decreased by 70% 
in the presence of strong CYP3A4 inducers (including, but not limited to ,avasimibe, 
carbamazepine, phenobarbital, pheny toin, rifabutin, rifampin, St. John's wort). Even 
though no clinical data are available, panobinostat blood concentrations may be reduced
by CYP3A4 inducers. Concomitant use of strong CYP3A4 inducers should be avoided.
Concomitant use of medications which are known sensitive CYP2D6 substrates (including , 
but not limited to , tamoxifen , propafenone, risperidone, thoridazine) are to be used with 
caution. Patients should be carefull y monitored for potential signs and s ymptoms of 
toxicity  and may  require dose titration or dose reduction of a sensitive CYP2D6 substrate 
which also has a narrow therapeutic window (e.g., the ratio of toxicity  exposur e is 
≤ 2-fold 
higher than the efficacious or therapeutic exposure).
Granulocy te growth factors (G- CSF) or red blood cell transfusion may  be used for severe 
neutropenia or for severe anemia, respectivel y, according to institutional guidelines.
Patients who were receiving recombinant ery thropoietin or darbepoetin alfa prior to 
starting stud y drug may continue to receive their pre -study  doses throughout the trial.
Palliative radiation therapy  may  be permitted, but the need for radiation therapy  is usuall y 
indicative of disease progression.
Analgesics for tumor -related pain can be maintained during the study . However, an 
increase in analgesic use for control of tumor -related pain may  indicate disease 
progression. If an increase in analgesic medication from study entry  is required during the 
study , the patient should be evaluated for progression of disease.
Anti- emetic medications may  be used at the discretion of the I nvestigator, but consider 
preferentiall y the use of metoclopramide. Prophy lactic anti -emetics exc ept those listed in 
Appendix 14.1 can be administered at the discretion of the Investigator. Intravenous 
dolasetron is contraindicated for preventing nausea and vomiting associated with cancer 
therap y based on FDA drug safet y warning (communication dated 17 -December -2010).
Concomitant use of anti -arrhythmic medicines (including , but not limited to ,amiodarone, 
disopy ramide, procainamide, quinidine, and sotalol) and other drugs known to prolong the 
QT int erval (including
, but not limited to , chloroquine, halofantrine, chlarithromycin, 
methadone, moxifloxacin, bepridil and pimozide) is not recommended.
DAC inhibitors (including valproic acid) for any  clinical indication are to be avoided 
while on panobinost at treatment.

Novartis Confidential Page 33
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
For additional information regarding these and other medications please refer to Appendix 
14.1 and for detailed safety  guidance , please refer to the I nvestigator’s Brochure.
6.3.1 Use of Bisphosphonates (or other concomitant agents)
Not applicable
6.4 Patient numbering, treatment assignment or randomization
6.4.1 Patient numbering
Each patient is identified in the study  by a Patient Number ( Patient No.), that is assigned when 
the patient is first enrolled in the roll-over study and is retained as the primary  identifier for 
the patient throughout his/her entire participation in the trial. The Patient No. consists of the 
Center Number (Center No.) (as assigned by Novartis to the investigative site) wit
h a 
sequential patient number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available to the investigator through theclinical trial database. 
Additionally ,an eCRF will be completed that identifies the patient by gender , date of birth , 
previous (parent) study , site/center and patient number.
6.4.2 Treatment assignment or randomization
All consented patients who meet all the inclusion criteria and none of the exclusion criteria 
are eligible to receive panobinostat.
6.4.3 Treatment blinding
Not applicable
6.5 Stud y drug preparation and dispensation 
The investigator or responsible site personnel must instruct the patient or caregiver to t ake the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All dosages prescribed to the patient and all dose changes during the study 
must be recorded on the Dosage Administration Record CRF.
6.5.1 Study treatment packaging and labeling
Panobinostat for the roll-over study  is provided as global open label supply , packed and 
labeled under the responsibility  of Novartis Drug Supply  Management. Study  treatment labels 
will be in the local language and compl y with the legal requirements of each country . They 
will include storage conditions for the drug but no information about the patient. Please note 
that clinical supplies of panobinostat will be labeled as “LBH589”. Should panobinostat 
become commerciall y available during the course of this study , drug may be sourced and 
labeled in -country  and the locall y-approved form and packaging will be used.
6.5.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study site, handled and 
stored safel y and properly , and kept in a secured location to which only the investigator and 

Novartis Confidential Page 34
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
designated site personnel have access. Upon receipt, thepanobinostat should be stored 
according to the instructions specified on the drug labels andin the current [Investigator’s 
Brochure].
6.5.3 Study drug compliance and accountability
6.5.3.1 Study drug compliance
Compliance will be assessed by the investigator and/or study  personnel at each patient visit 
and information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit.
6.5.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatm ent in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits and at the completion of the study . Patients will be asked to return 
all unused study  treatment and packaging on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  logto the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
6.5.3.3 Handling of other study  treatment
Not applicable.
6.5.4 Disposal and destruction
The drug suppl y can only be destroy ed once the study  drug accountability  check has been 
performed by the monitor. The supply of panobinostat can be destro yed at the local Novartis 
facility , Drug Supply  group or third part y, as appropriate.
7 Visit schedule a nd assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be suppor ted in the patient’s source 
documentation. Patients must return to the study  center at least on a quarterly  (every  12 +/-2 
weeks) basis for resupply  of study  medication. Patients may return to the study  center more 
frequentl y at the physicians’ discretion as clinically  indicated or 
as per standard of care; 
however, data from these visits will not be captured in the eCRF, but rather only  in the source 
documents at the study  center.
The table indicates in the “Category ” column which assessments produce data to be entered in 
the database (D).

Novartis Confidential Page 35
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Table 7-1 Visit evaluation schedule
CategoryProtocol 
reference
section 
EnrollmentQuarterly (every 12 +/- 2 weeks ) 
visits during treatment phaseEnd of treatment 
(EoT)30 day safety
follow -up post 
last dose of study 
drug /End of 
Study
Visit Number 1 2 3 4 5 6 7 8 9+ 777 501/778
Obtain informed consent D 7.1.2 x
Parent Study History (e.g. subject’s 
previous study , site and patient number)D 7.1.2.3 x
Demography (e.g. gender and date of 
birth)D 7.1.2.3 x
Relevant medical histor y/current 
medical conditionsD 7.1.2.3
Inclusion/exclusion criteria D 5.2/ 5.3 x
Adverse events and serious adverse 
events*D 8.1.1 & 
8.2.2 continuousx
s.a. oral panobinostat dosing 
administration D 7.1.3 x continuous
Pregnancy testing D, S 7.1.4 continuous
Confirmation of Clinical Benefit from 
Study TreatmentD 7.2.1xx x x x x x x x
End of treatment D 7.1.5 x
Study Evaluation Completion D 7.1.5 x
*SAEs will be reported to the Novartis safety database within 24 hours of investigator or treating physician’s knowledge of th e event from the time the 
patient signed informed consent until at least 30 days after the patient stopped study treatment (see Section 8 ).
Note: All other assessments are performed as per standard of care at the site and will not be captured in the CRF.

Novartis Confidential Page 36
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
7.1.1 Molecular pre -screening 
Not applicable.
7.1.2 Screening
At the enrollment visit, the patient will need to complete a written informed consent .There 
will be no screening period for this study . Once consented, patients will be evaluated for 
eligibility  via the inclusion and exclusion criteria.
7.1.2.1 Eligibility  screening
Not applicable.
7.1.2.2 Information to be collected on screening failures
Not applicable.
7.1.2.3 Patient demographics and other baseline characteristics
For patients that are eligible to participate in this roll-over study , the patients’ gender, date of 
birth, previous study , site/center and subject number , and relevant medical history  will be 
collected.
7.1.3 Treatment period
The starting dose of panobinostat should be the same as the dose that was given in the parent 
panobinostat study . A quarterl y (every  12 +/- 2 weeks) supply  of panobinostat will be 
dispensed to the patient/or as per local practice.
Patients must return to the study  center on a quarterl y (every 12 +/- 2 weeks ) basis for 
resupply  of study  medication at which time limited drug dispensing information will be 
collected. At every quarterly visit, the investigator is required to confirm that the patient 
continues to have clinical benefit and may  continue receiving study  treatment. At this time the 
dose of panobinostat is based on the investigator’s judgment. The patients may return to the 
clinic more frequentl y at the phy sician’s discretion as clinically  indicated or as per standard of 
care. These unscheduled visits will only be captured in the source documents at the study 
center and not in the eCRF. 
All adverse events and serious adverse events will be collected and 
documented in the eCRF. 
The study  is expected to remain open for 5years or until such time that enrolled patients no 
longer need treatment with panobinostat and all follow -up is completed , whichever comes 
earlier.
7.1.4 Pregnancy  and assessment of fertility
Since highl y effective contraception is required during the study , female patients of child 
bearing potential are required to test negative for a pregnancy  (either with serum testing if 
routinely /locall y available or urine pregnancy test) before enrolling into the stud y. 

Novartis Confidential Page 37
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Women of child -bearing potential, defined as all women physiologically  capable of becoming 
pregnant, unless they are using highly  effective methods of contraception during the study  
and for 3 months after the final dose of panobinostat .
Highl y effective contraception is defined as either:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are not acceptable met hods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n case of 
oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by follow up hormone level assessment.
Male sterilization (at least 6 months prior to enrolling). For female patients on the study  
the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contraception or placement of an 
intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transderma l hormone contraception. Women using hormonal 
contraceptives should additionally  use a barrier method of contraception. 
If patient has tested negative at the end of study  on the parent study , no pregnancy  testing is 
required if enrollment into this study  is carried out on the same day or within few days 
(maximum 5 day s) from each other.
Female patients of child bearing potential are required to perform monthly  home urine 
pregnancy  tests and complete a simple diary  with the dates and the outcome of the home
urinary  test while on study  treatment and during safet y follow -up (30 days after the final dose 
of study  medication).
A pregnancy  test (either with serum testing if routinely /locall y available or urine pregnanc y 
test) on female patients of child bearing p otential is required at the final study  visit.
Any positive results will be recorded in the database and followed up as per Section 8.4.
7.1.5 Discontinuation of study treatment
Patients will continue to be treated until they are no longer benefiting from panobinostat 
treatment, develop unacceptable toxicities ,withdraw consent, are non-compliant to the 
protocol, lost to follow -
up or other administrative problem, the investigator feels it is no 
longer in the patient’s best interest to continue panobinostat therap y(e.g., pregnancy , disease 
progression, adverse events) or the patient dies, whichever comes first.
At the time the patient discontinues study  treatment, a visit should be scheduled as soon as 
possible, at which time the assessments listed for the End of Treatment (EOT) visit will be 
performed. EOT information will be completed in the eCRF giving the date and reason for 
stopping the study  treatment (see Section 7. 1.5.1).
At a minimum, all patients who discontinue study  treatment, including those who refuse to 
return for a final visit, will be contacted for a safet y evaluation approximately  30 days 

Novartis Confidential Page 38
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
following the last dose of study  treatment. The completion of the Study  Evaluation 
Completion eCRF page is required any  time a patient discontinues from the study  and must be 
completed 30 day s after the end of treatment.
Patients who discontinue study treatment should be considered withdrawn from the study  after 
the final visit assessments are performed or when it is clear that the patient will not return for 
these assessments.
If a study  withdrawal occurs, or if the patient fails to return for visits, the investigator must 
determine the primary  reason for a patient’s withdrawal from the study  and record this 
information on the appropriate eCRF page.
A patient will reach the end of study  when panobinostat treatment is permanentl y 
discontinued and there will be nofurther follow -up study  visits.
7.1.5.1 Criteria for premature patient withdrawal
Patients may voluntaril y withdraw from the study or be dropped from it at the discretion of 
the investigator at an y time.
Patients may  be withdrawn from the study  if an y of the following occur:
1.Adverse event(s) .
2.Subject withdrew consent .
3.Lost to follow -up.
4.
Administrative problems.
5.Death .
6.Disease progression.
7. Protocol deviation.
8.Pregnancy .
9.Study  terminated by  sponsor
7.1.5.2 Replacement policy
Not applicable. 
7.1.6 Withdrawal of consent
Patients may voluntaril y withdraw consent toparticipate inthestudy foranyreason at any 
time.Withdrawal of consent occurs only when apatient does notwant toparticipateinthe 
study anylonger, anddoes notwant anyfurther visits orassess ments, anddoes notwant any 
further study related contact.
Novartis will continue toretain anduseallresearch results thathave alread ybeen collected 
forthestudy evaluation. Allbiological samplesthat have already beencollected maybe 
retained andanalyzed
atalater date (or as required by local regulations).
Ifa patient
withdraws consent, theinvestigator should makea reasonable effort (e.g. telephone,
e-mail, lette r) to understand t he pri mary reason for this de c ision and rec ord this in f orm ation.
Study treatmentmust be discontinued andnofurther assess mentsconducted.

Novartis Confidential Page 39
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Further attempts tocontact thepatie ntarenot allowed unless s afety findings require 
communication or follow up.
7.1.7 Follow up for safety  evaluations
All patients must be followed up for safety  evaluations for 30 day s after the last dose of study  
treatment. At the end of this period, the investigator should contact the patient to inquire about 
any adverse events or serious adverse events observed during this period. This could be done 
via a phone contact. Following this ,there are no further follow- up study  visits .
Patients lost to follow up should be recorded as such on the appropriate eCRF. For patients 
who are lost to follow -up, the investigator should show "due diligence" by  documenting in the 
source documents steps taken to contact the patient, e.g., dates of telephone calls, registered 
letters, etc.
Data collected should be added to the Adverse Events e CRF .
7.1.8 Lost to fo llow- up
Forpatie ntswhose status is unclear because they failtoappear forstudy  visits without stating 
anintention towithdraw consent, theinvestigator should show "due diligence" bycontacting 
thepatient, family orfamily physician asa
greed intheinfor medconsent andbydocumenting 
inthesource docu ments steps taken tocontact thepatient, e.g. dates oftelephone calls, 
regis
tered letters,etc.Apatie ntsho uldnot be considered losttofollow -upuntil duediligence 
hasbeen completed. Patients losttofollow upshould berecorded assuch ontheappropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
At every  quarterl y visit, the investigator is required to confirm that the patient continues to 
have clinical benefit and may  continue receiving study  treatment. 
7.2.2 Other assessments
No additional tests will be performed on patients entered into this study .
7.2.3 Safety  and tolerability assessments
Safety  will be monitored by collecting of the adverse events at every  visit. For details on AE 
collection and reporting, refer t o Section 8.
7.2.4
Pharmacokinetics
Not applicable. 
7.2.4.1 Analytical method
Not applicable.

Novartis Confidential Page 40
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
7.2.5 Resource utilization
Not applicable.
7.2.6 Patient reported outcomes
Not applicable.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Any ongoing adverse events from the parent study  will be captured as medical history  in the 
roll-over database. Any AE that begins (or worsens) after signing of the informed conse nt for 
the roll-over and during the 30-day (or 28-day) safet y follow -up period defined in the parent 
protocol should be reported in both clinical databases.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed according to the current version of Common Terminology 
Criteria fo r Adverse Events (CTCAE).
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life -threatening, corresponding to Grades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in this study; rather, information about deaths will be collected through the EOT 
eCRF page.
The occurrence of adverse events should be sought by non-directive questioning of the patient 
(subject) during the screening process after signing 
informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screeni ng process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2. Its duration (start and end dates)

Novartis Confidential Page 41
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
3.Its relat ionship to the study  treatment (reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5. Whether me dication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
If the event worsens the event should be reported a second time in the CRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, if 
improvement to a lower grade is determined a new entry  for this event should be reported in 
the CRF noting the start date when the event improved from having been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by use 
of appropriate 
method (for example, as per RECIST criteria for solid tumors or as per Cheson's guide lines 
for hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required b y the protocol in which case the lab oratory abnormalit y would still, by definition, be 
an adverse event and must be reported as such.

Novartis Confidential Page 42
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
8.1.3 Adverse events of special interest 
Adverse events of special interest (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by the investigator to the sponsor may 
be appropriate. Such events may require further investigation in order to characterize and 
understand them. 
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data and including acute pancrea titis, interstitial lung disease, ischaemic colitis, hepatic 
dysfunction, pneumonia, sepsis, renal dysfuction, cardiac failure, ischaemic heart disease, 
pericardial effusion, tachy arrhy thmias, and venous thromboembolism. AESI s are discussed in 
detail in t he Investigator Brochure.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defe ct
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitalization, 
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
Elective or pre -
planned treatment for a p re-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an e mergency  outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality, occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any SAE that begins or worsens after signi ng of the informed consent for the roll-over and 
during the 30 -day (or 28 -day) safety  follow up period defined in the parent protocol should be 
reported as an adverse event in both clinical databases; however, onl y one SAE will be sent to 
Novartis .

Novartis Confidential Page 43
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Any SAE that begins or worsens during the 30- day (or 28 -day) safety follow -up period 
specified in the parent study should have an SAE report submitted to Novartis with the 
parent protocol stud y number. 
Any SAE that begins or worsens after the 30-day (or 28 -day)safety  follow -up period 
specified in the parent study should have an SAE report submitted to Novartis with the 
roll-over protocol stud y number. 
Any additional information for the SAE including complications, progression of the initial 
SAE, and recurrent episodes must be reported as follow -up to the original episode within 24 
hours of the investigator receiving the follow -up information. An SAE occurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
It is important to use the right SAE form with the correct protocol number for these two 
scenarios, to avoid confusion in SAE processing. For a patient already  on the roll-over 
protocol but follow up information is reported for the previous SAEs in the parent protocol, it 
must be clearl y labeled that this is for the parent protocol number.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investiga tor suspects a causal relationship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report .Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated and whether the patient 
continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure (new occurrence) or 
Package Insert and is thought to be related to the Novartis study  treatment, an oncology  
Novartis Drug Safet y and Epidemiology  (DS&E) department associate may urgently  require 
further information from the investigator for Health Authority  reporting. Novartis may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. 
Suspected Une xpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicabl e. This is an open-label stud y.

Novartis Confidential Page 44
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
8.4 Pregnancies
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence . The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnanc y should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  Novartis Drug Safety  and Epidemiology  Department (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to panobinostat of any pregnancy  outcome. Any SAE experienced 
during pregnancy  must be reported on the SAE Report Form .
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother. The collection of this information could last for up to12 
months following the birth of the child. The Study  Doctor and Novartis may decide what 
pertine nt information is collected as necessary  or indicated based on the study .
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety  information collected between [Investi gator Brochure] updates 
will be communicated in the form of Investigator Notifications. This information will be 
included in the patient informed consent and should be discussed with the patient during the 
study  as needed.
8.6 Data Monitoring Committee
Not applicable. 
8.7 Steering Committee 
Not applicable. 
9 Data collection and management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .

Novartis Confidential Page 45
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced an y new or worsened AEs) at the end of their scheduled s tudy period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’ s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to ass ist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop yis given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adher ence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully  validated secure web-enabled software that conforms to 21 CFR 
Part 11 requirements, Investigator site staff will not be given access to the EDC system until 
they have been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF sis 
complete, accurate, and that entry  and updates are performed in a timely  manner.

Novartis Confidential Page 46
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designated CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respond promptly  to queries and to make any necessary 
changes to the data.
At the conclusion of the study , the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and made available for data analysis. 
Authorization is required prior to making any database changes to locked data, by joint 
written agreement between the Global Head of Biostatistics and Data Management and the 
Global Head of Clinical Development.
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data f or archiving at the investigational site.
10 Statistical methods and data analy sis
10.1 Analysis sets
The following anal ysis sets will be used for statistical anal ysis and data reporting.
10.1.1 Full A nalysis Set
Not applicable.
10.1.2 Safety
 Set
The Safet y Set includes all patients who received at least one dose of study  medication after 
enrolling into the roll-over protocol.
10.1.3 Dose -determining analy sis set
Not applicable.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data characteristics willbe summarized descriptivel y for the 
Safety  Set.
10.3 Treatments (study  treatment, compliance)
Dose administration data will be summarized using the Safet y Set.
10.4 Primary  objective
The primary  objective is to evaluate long term safet y as assessed by the occurrenc e of 
AEs/SAEs.

Novartis Confidential Page 47
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
10.4.1 Variable
See Section 10.5.3.
10.4.2 Statistical hy pothesis, model, and method of analy sis
No hy pothesis will be tested. 
10.4.3 Handling of missing values/censoring/discontinuations
Not applicable.
10.4.4 Supportiv e analy ses
No supportive analysis will be performed.
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable.
10.5.2 Other secondary  efficacy  objectives
The secondary  objective of the study  was to evaluate clinical benefit as assessed by the 
investigator. Proportion of patients with clinical benefit as assessed by the investigator will 
be summarized at scheduled visits .
10.5.3 Safety  objectives
The assessment of safet y will be based mainly  on the frequency  of AEs and SAEs.
10.5.3.1 Analysis set and grouping for the analy ses
The overall observation period will be divided into two mutually  exclusive segments:
1.
on-treatment period: from day  of first dose of study  medication to 30 day s after last dose 
of study  medication
2.post-treatment period: starting at day  30+1 after last do se of study  medication.
10.5.3.2 Adverse events (A Es)
Summary  tables of adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the post-treatment periods) will be listed and those collected during the 
post treatment period are to be flagged. 
The incidence of treatment emergent adverse events (new or worsening from baseline) wil
l be 
summarized by system organ class and/or preferred term, severity  (based on CTCAE grades), 
type of adverse event, relation to study  treatment. 
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and 
tabulated b y type of adverse event. 

Novartis Confidential Page 48
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
10.5.3.3 Other safety  data
Not applicable.
10.5.3.4 Tolerability
Not applicable.
10.6 Interim analy sis
Not applicable.
10.7 Sample size calculation
Not applicable.
10.8 Power for analy sis of key secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature page confirming his/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent 
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their CRFs.

Novartis Confidential Page 49
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be 
informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Additional consent form 
Not applicable. 
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement.
11.5 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly accessible database of clinical study  results.
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
Novartis -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by applicable law, to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospital 
records, clinical and office charts, laboratory notes, memoran
da, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.

Novartis Confidential Page 50
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Data collection is the responsibility  of the clinical trial staff at the site under the supervi sion of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the study . The investigator should ensure the accuracy , completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary ) and should not obscure the original 
entry . For electronic CRFs an audit trail will be maintained by the system. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
applicable regulations and/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completio n of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7 Confidentiality  of study  documents and patient re cords
The investigator must ensure anon ymity of the patients; patients must not be identified by 
names in any documents submitted to Novartis. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient ide ntification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involve d in the 
treatment or eva luation of patients at the site, prior to study  start.

Novartis Confidential Page 51
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
study  to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study  this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, N ovartis should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. UK requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.

Novartis Confidential Page 52
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
13 References (availa ble upon request)
Atadja P (2009) Development of the pan -DAC inhibitor panobinostat (LBH589): successes 
and challenges. Cancer Lett;280:233-241.
Atadja P (2011) HDAC inhibitors and cancer therapy . In: SM Gasser and Li E(Eds), 
Epigenetics and Disease, Progress in Drug Research 67 DOI 10.1007/978-3-7643-8989-5_9.
Boumber Y, Issa JP (2011) Epigenetics in Cancer: What’s the Future? Oncology ;25:1 -13.
Duvic M, V u J (2007) Vorinostat: a new oral histone deacet ylase inhibitor approved for 
cutaneous T -cell ly mphoma. Expert Opin I nvestig Drugs;16:1111 -1120.
Duvic M. Dummer R. Becker JC, et al (2012) Panobinostat activity  in both bexarotene -
exposed and naïve patients with refractory  cutaneous T -cell ly mphoma: Results of a phase II 
trial. European Journal of Cancer available at sciencedirect.com .
Grant C, Rahman F, Piekarz R, et al (2010) A new therap y for cutaneous T -cell ly mphoma 
and a potential therapy for solid tumors. Expert Rev Anticancer Ther;10:997 -1008.
Hamberg P, Woo MM, Chen L C, et al ( 2011) Effect of ke toconazole -mediated CYP3A5 
inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone 
deacety lase inhibitor. Cancer Chemoth Pharmacol;68:805-813.
Hidaka M,Fujita K, O gikubo T,et al (2004) Potent inhibition bystarfruit of human 
cytochrom e P 450 3A (CYP 3A)activity, Drug Metab Dispos 2004; 32: 581.
Issa JP, Kantarijan HM, Kirkpatrick P(2005) Azacitidine. Nat Rev Drug Discov;4:275 -6.
Issa JP (2007) DNA methy lation as a therapeutic target in cancer. Clin Cancer Res;13:1634 -
1637.
Kantarijan H, Issa JP, Rosenfeld CS, et al (2006) Decitabine improves patient outcomes in 
myelodysplastic s yndromes:results of a phase III randomized study . Cancer; 106:1794-1803.
Prince MH, Bishton MJ, Johnstone RW (2009). Panobinostat ( LBH589): a potent pan -
deacety lase inhibitor with promising activit y against hematologic and solid tumors. Future 
Oncol;5(5):601-612.
Shapiro GI, Frank R, Dandamudi UB, et al (2012) The effect of food on the bioavailability  of 
panobinostat. An orall y active pan -histonee deacety lase inhibitor, in patients with advanced 
cancer. Cancer Chemother Pharmacol;69:555 -562.
Shou M, Hay ashi M, Pan Y, et al (2008) Modeling, prediction, and in vitro in vivo correlation 
of CYP3A4 induction. Drug Metab Dispos;36:2355
–2370.
S
ynold TW, Ta kimoto CH, Do roshow JH,et al (2007) Escalating and Pharm acologi cal S tudy 
of Oxa liplatin in Adult Cancer Pa ti entswith Impai red Hepa ticFunc tion: A Nationa l Cancer 
Institute O
rgan Dysfunc tionW o rking Group S tudy, C linCancer Re s.2007 13; 3660.
Younes A, Sureda A, Ben -Yehuda D, et al (2012) Panobinostat in patients with 
relapsed/refractory  Hodgkin’s Ly mphoma after autologous stem -cell transplantation:Results 
of a phase II stud y. J Clin Oncol published ahead on April 30, 2012 as 
10.1200/JCO.2011.38.1350.

Novartis Confidential Page 53
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
14 Appendices
14.1 Concomitant medication
In genera l,m edica tions listed inTable 14-1 should be avoided and medica tions listed in
Table 14-2 and Table 14-3 aretobe used with caution when co -administ eredwith
panobinost at.The useof any ofthe drugs inTable 14-1, Table 14-2 and Table 14-3in
combin ation with panobinost at must bedis cussedwith theSponsor.
14.1.1 Medications which are k nown toprolong theQTinterval a nd/or indu ce
Torsades de pointes ve ntricular arrhyt hmia should beavoided
It is of greatimpo rtance toavoid such d rugs listed be lowinTable 14-1 incombin ation with
panobinost at,espec ially inthepresence o f electroly teabno rmalities,notabl y decr eased
potassium or magne sium leve lscommon ly asso ciated with diureticusage.
This isnot a c omprehensive listof medi cations which may pr olong theQT interval
a
nd/or induceTorsades de pointe s.This listof medica tions was d evelopedincollabora tion
with an ext ernal car diology con sultant and represen tsthose m edications which are deemed to
have an unac c epta bleriskof co-a dminist rationwith panobinost at.
Thefollowi ng website ma y bereferenced as a s upplemental gu idefor drugs which have b een 
asso
ciated with Torsades de point e s or pr olonging theQTinterval but atthis time lack 
substantia l evide n ce for causi ng Torsades de p ointes:azcert.org/medi cal-pros/drug-lists/d rug-
lists.cfm.(version 3/25/2008 ).
Medi cations listed on the we bsite which do not a ppearinTable 14-1 a bove ma y b e used with 
caution atthe discre tionofthe inv estigator.
Ondansetron (a known CYP2D6 substrate, see Table 14-3) hasp ro longation but has not b een
shown tocauseTorsades de point es. Therefore, ondansetron is not p erseprohibit ed when
combin edwith pano binost a t but caution is to be ex ercised and c lose monito ring forsigns and
symptoms ofQTprolon ga tion is recomm ended.
Table 14-1 Medications which are known to prolong the QT interval and/or induce 
Torsades de Pointes to be avoided
AllClass IA a ntiarrhythmi cs Quinidine
Procainami de
Disopyrami de
anyotherclass IAantiarrhythmic drug
AllClassIII antiarrhythmics Amiodarone
Sotalol
Dofetilide
Ibutilide
anyotherclass III antiarrhythmic drug
Macrolide antibiotics* Erythromycin
clarithr omycin
Quinolone antibiot ics* Sparfloxa cin
Antifungals pentamidi ne

Novartis Confidential Page 54
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Antima larials Halof antrine
chloroqui ne
Antihistamin es Astemizo le
terfenadi ne
Anti-emetics Chlorpromazine
Dom perido ne
Droperidol
dolasetr on(intraven ousand oral)^
Antips ychotics Thioridazi ne
Mesoridazi ne
Chlorpromazine
pimozi de
Miscell aneous drugs arsenic trio xide
bepridil
domperido ne
cisapride
levom ethadyl
methado ne
*Note: azithromycin, ciprofloxaci n,levofloxacin, pefloxaci n,ofloxacin, tosufloxacin , difloxa cin,
temafloxaci n,fleroxa cin,acrosoxaci n,nalidixic a cidandenoxacin ar e allowe d.
^ I ntraven ousdolas etron is contraindicat edforpreventi ng naus eaandvomiti ng ass ociatedwith
chem otherapy basedon FDAdrugsafety comm unicationdated De cember 17, 2010.Based onthis
finding, bo thintravenous andoral dolasetr onare prohibi ted to be takenwithpanobinostat.
14.1.2 Medications which are known strong CYP3A 4/5 inhibitors to be 
avoided 
Panobinost at isasubst rate of CYP 3A4/5 with minor involv ement of CYP2D6, a nd CYP2C 19
inin vitro e
valuation ofitsmeta bolism. Thus, a c linical drug-dru g interaction study was 
conducted usin g k etoconazole, a strong CYP3A inhibito r ,incombin ation with panobinost at 
in stu d
y CLB H589B2110.
Multiple ketoconazoledoses at 400 mg inc reased C max andAUC of panobinost a t by 1.6-and 
1.8-f old,res p ectiv ely, b utwith no chan geinTm axor half- lives in14 cancers pa tients.Theless 
than 2-f old inc r ease in panobinost at AUC upon co-a dminist ration of a str ong CYP 3A 
inhibitor isconsid
ered a weak drug inhibition a nd not c linically relevant, as
panobinost at dos es at l east2-foldgreater than theevaluated 20 mgdose ( i.e., 40 mg and 60
mghave been s afel y administ eredinpatients.Thus, co-administ ration ofpanobinost a t with
amoderateor weak CYP3A inhibitor is allowed.However, clini calmonito ringofsigns
and sy mptoms of panobinost at treatment related toadver s e ev entsisrecomm ended when
long
-term (≥ 1 w eek) conc omit ant a dminist ration of an y strong CYP3A inhibito r s and
panobinost a t ismedi cally indicated or investigated ina clinical study.
Patientswith impaired liver fun ction (as defined by NCI C TEP criteria) ( Synold et al 2007 ) 
are recomm ended not torec eive p anobinost at conc omit antly with strong CYP3A
inhibito rs b
ecause pote ntia l interactionhas not b een e stablishedinthispopul ation.

Novartis Confidential Page 55
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Table 14-2 Medic ations whichareknown s trong CYP3A4/5 inhibitorsto be used 
with caution
Macrolide antibiotics* Telithromycin
troleandomycin
Antifungals (azo les) Ketoconazole
Itraconazole
Posaconazo le
voriconazole
Antidepres sants nefazo done
HIV pr oteaseinhibitor s: Indina vir
Nelfinavir
Ritonavir
Saquinav ir
lopina vir
Miscell aneous drugs or pr oducts 1Starfruit and pomegranate product a ndjuice
conva ptan
*azithromycinandregularorangejuice are a llowed.
1Hidaka et al (2004).
Althoughclarithr omycin is a k nown strong CY P3A inhibi tor, it is also known to prol ong QT intervals
which i s listedinTable 14 -1andis prohibit edto be takenwith p anobinos tat. This dr ugis thus not listed
again in Table 14 -3.
This isnot a c omprehensivelistof medi cations which may inhibit CYP3A 4/5. Thea bove list 
w
as compil ed by using informa tion liste d und er “draft g uida nce for indust ry, drug interaction 
studi es,CDER 2006”, Indiana Univer sit y Sc hoolof Medic inedrug i nteraction t ables at 
medic ine.iupui. edu/c linph arm/DD Is/ClinicalT able. aspand “d ruginteraction datab ase” from
Univer sit y of Wash ington.
Addition al updated ver sions with moderat e and w eak CYP 3A inhibito rs,whichare meant
to be used as a guide, may be found at the following website: 
medic ine.iupui. edu/c linph arm/DD Is/ClinicalT able. asp.
14.1.3 Medications which are k nown CYP2D6subst ratestobe us edwith
caution
Panobinost at was a lsoshown tobe a CYP 2D6 inhibitor (Ki0.17 µ M)in vitro. Thus, c linica l 
drug-d ruginteraction study with panobinost a t as CYP 2D6 inhibitor and dextrome thorpan
as C
YP2D6 subst ratewas re cently conducted instudy[CLB H589B2109] .
Multiple panobinost a t doses incre ased C maxand A UCof dextr omethor phan b y a m eanof 1.8-
and 1.6-f oldrespe c tively, but with no change inTm axin17cancer pa tients.Anapproximately 
2-fold inc r ease indextrome thorphan AUC upon c o-administ ration with panobinost a t
indicated thatin vivo CYP 2D6 inhibition of panobinost atisweak.
Asthestudy was c onducted using a sensitive CYP 2D6 subst ratewhichresultedina
weak inhibition, drugs w itha large the rapeutic indexsuch as a nti-eme tics,anti-
hyperte nsives,and anti-depre s sa ntsare gen erally safe tobe co -administ eredwith panobinost at.

Novartis Confidential Page 56
Amended Protocol Version 01 Clean Protocol No. CLBH589B2402B
Patientsshould be carefully monito red for potential signs and sy mptoms oftoxicity and ma y 
require dose tit ration ordose reduction of a sens itive C YP 2D6 subst ratewhich alsohave
a narrow therap eutic window (e.g.,theratioof toxicity ex posu reis≤ 2-f oldh igh er than
the efficacious or the rapeutice x posu re).
Table 14-3 M edica tionswhichareknown CYP2D6 substrat estobeused with 
cauti on
Beta blo ckers S-metoprol ol
Propaf enone
timol ol
Antips ychotics Aripiprazole
Haloperidol
Risperidone
thioridazi ne
Antidepres sants Amitriptyline
Clomiprami ne
Desiprami ne
Imiprami ne
Fluoxetine
Paroxeti ne
Venlafaxi ne
dulox etine
Antiarrhythmics Mexilletine
flecaini de
Others Codeine
Dextrom ethor phan
Tamoxif en
tramadol
Anti-emeti cs ondans etron^
^ Intraven ousdolas etron is a CYP2D6 substrate andcontraindica tedforpreventing naus eaand 
vomiti ngassociated wi thchemotherapy basedonFDA drugsafety comm unicationdated Decem ber
17,2010. Pl ease seeTable 14 -1.
This isnot a c omprehensive listof CYP 2D6 substrates.Addition alupdated v ersions of
this list, whichare meant to be used as a guide, ma y b e found at thefollowing website: 
medic ine.iupui. edu/c linph arm/DD Is/ClinicalT able. asp.
